Caroline Popper, M.D., M.P.H.
Caroline Popper currently serves as Co-Founder and President of Popper and Company.
Dr. Popper has more than 21 years of hands-on biotech/life sciences operating experience. An internist and pathologist, she combines medical and scientific perspective with knowledge gained from managing a wide spectrum of life sciences businesses in diagnostics, devices and drug discovery. Her business management experience in both Fortune 500 and start-up settings – and extensive track record creating strategic and business partnerships in the biotech arena – is key to the insights she provides to her clients.
During a 10-year career at Becton Dickinson (NYSE: BDX), Dr. Popper’s global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding General Manager of BDGene, a start-up focused, with its partner Millennium Pharmaceuticals, on development of novel cancer diagnostics. From 2000 to 2002, she was the Chief Business Officer for MDS Proteomics, a drug discovery company with operations in the U.S., Canada and Europe.
Today, Dr. Popper and her colleagues at Popper and Company leverage their extensive knowledge of the trends and forces shaping the life sciences industry and its participants. The firm has focused expertise in working with clients whose product or service is targeted at inefficiencies in the healthcare delivery system and/or at the convergence of healthcare and technology.
Dr. Popper received her medical degree from the University of the Witwatersrand (South Africa) and her M.P.H. from Johns Hopkins University (Baltimore). She completed her residencies in internal medicine and in pathology at Johns Hopkins. Dr. Popper is currently a board member of NanoMR, Innovative Biosensors, Rarecyte, LBT Innovations (Australia) and Pronota nv.